Retatrutide and Visceral Fat: Trial Evidence

Retatrutide and visceral fat are the subject of ongoing clinical research into this investigational triple hormone receptor agonist, which activates GLP-1, GIP and glucagon receptors simultaneously. Retatrutide holds no marketing authorisation in the UK or elsewhere and can be accessed only within an authorised clinical trial. Phase 2 data published in the New England Journal of Medicine in 2023 reported reductions in body weight and, in imaging sub-studies, reductions in visceral adipose tissue volume. This article summarises what the trial evidence shows, its limitations, the reported safety profile and the current regulatory position in the UK.

What is retatrutide and how does it work in the body?

Retatrutide is an investigational triple agonist activating GLP-1, GIP and glucagon receptors simultaneously. The glucagon component is hypothesised to increase energy expenditure and promote visceral fat breakdown, but this effect in humans remains under investigation.

Retatrutide is an investigational triple hormone receptor agonist that simultaneously activates receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon, a combination not shared by any currently authorised medicine. It is not licensed in the UK or anywhere else, and it can be accessed only within an authorised clinical trial.

Each of the three receptor pathways contributes differently to energy balance. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects shared with licensed medicines such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro).^[7][8] GIP receptor activation is thought, on the basis of early clinical and preclinical data, to enhance insulin secretion and may influence fat storage and energy expenditure.^[9][10] Glucagon receptor activation is hypothesised to increase energy expenditure and promote the breakdown of stored fat, including fat in visceral depots around the abdominal organs; however, the extent to which this translates to selective visceral fat reduction in humans remains under investigation.^[10][1]

The theoretical rationale for targeting all three receptors is that the combined signalling may produce greater reductions in body weight and adiposity than dual or single agonism alone. Because retatrutide remains investigational, these mechanisms have been studied only in trial populations under controlled conditions, and the findings cannot be generalised to routine clinical use. Researchers are continuing to characterise how the glucagon component in particular influences body composition, including its specific effects on visceral adipose tissue.

What have clinical trials found about retatrutide and visceral fat?

Phase 2 imaging sub-studies reported reductions in visceral adipose tissue volume, with Phase 3 data from TRANSCEND-T2D-1 and TRIUMPH extending the evidence base. Detailed body composition endpoints from the full Phase 3 programme have not all been published.

Phase 2 trial data published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported substantial reductions in body weight among participants receiving retatrutide over 48 weeks, with findings that prompted further investigation into changes in body composition, including visceral fat. Participants in the higher-dose groups achieved mean body weight reductions that were among the largest reported for a pharmacological intervention in a trial of this length at that time, according to the authors' own comparison within that publication; cross-trial comparisons should be interpreted with caution.^[1][2]

Imaging sub-studies within some trial arms assessed changes in visceral adipose tissue specifically, given that visceral fat is more strongly associated with cardiometabolic risk than subcutaneous fat. Reductions in visceral fat volume were reported in these sub-studies, though the precise figures varied by dose and measurement method.

The Phase 3 programme includes the TRIUMPH series (examining retatrutide in obesity) and the TRANSCEND series (examining retatrutide in type 2 diabetes).^[3][4] Topline results from TRANSCEND-T2D-1, published in The Lancet, and initial TRIUMPH readouts presented at major diabetes and obesity congresses have extended the evidence base beyond Phase 2.^[3] However, detailed body composition endpoints, including visceral adipose tissue data, from the full Phase 3 programme have not all been reported, and conclusions about the magnitude and durability of retatrutide's effects on visceral fat should still be treated as preliminary pending complete publication.

What are the limitations of the research so far?

The most granular visceral fat data come from Phase 2 imaging sub-studies involving only a subset of participants, limiting statistical power and generalisability. Full body composition results from the Phase 3 TRIUMPH and TRANSCEND programmes are not yet available.

Although Phase 3 readouts from TRANSCEND-T2D-1 and initial TRIUMPH data are now available, detailed body composition outcomes, including visceral adipose tissue measurements, have not been fully reported across the Phase 3 programme. The most granular published data on visceral fat changes remain those from imaging sub-studies conducted within the Phase 2 trial, which was not primarily designed to measure visceral adipose tissue as a primary endpoint.

Visceral fat measurements in clinical trials are typically obtained using magnetic resonance imaging or computed tomography, both of which are resource-intensive and not performed in all participants. Body composition sub-studies therefore often involve a subset of the trial population, which can limit the statistical power and generalisability of the findings. Different trials also use different imaging protocols and anatomical reference points, making direct comparisons between studies difficult.

The trial populations enrolled in Phase 2 and Phase 3 studies are carefully selected and may not reflect the full range of people who might eventually be eligible for a treatment of this kind. Factors such as age, ethnicity, baseline visceral fat burden, presence of type 2 diabetes and concurrent medications can all influence how body fat responds to pharmacological intervention. Until complete body composition data from the TRIUMPH and TRANSCEND programmes are published, conclusions about retatrutide's effects on visceral fat should be regarded as preliminary.

What side effects and safety concerns have been reported in trials?

The most commonly reported side effects are gastrointestinal, including nausea, vomiting, diarrhoea and constipation, generally more frequent at higher doses. Heart rate increases have also been observed and are being further characterised in Phase 3.

The most commonly reported side effects of retatrutide in clinical trials have been gastrointestinal in nature, consistent with the GLP-1 receptor agonist component of its mechanism. These include nausea, vomiting, diarrhoea and constipation, which were generally more frequent at higher doses and during dose escalation periods. In the Phase 2 trial (Jastreboff et al., NEJM 2023), most gastrointestinal events were described as mild to moderate in severity, though they led to discontinuation in a proportion of participants. Phase 3 safety data from TRANSCEND-T2D-1 have broadly confirmed this gastrointestinal profile.

Heart rate increases have also been observed in trials, a finding noted with other agents in this drug class. This has been hypothesised to relate to glucagon receptor activity, though the precise mechanism in humans has not been established. The Phase 3 programme is designed in part to characterise the long-term clinical significance of this finding.

Because retatrutide shares the GLP-1 receptor agonist mechanism with licensed medicines, the safety considerations relevant to that class, including the potential for gastrointestinal adverse events and the need for caution in people with a history of pancreatitis, are relevant to its trial use. Participants in the TRIUMPH and TRANSCEND trials are excluded if they are pregnant, breastfeeding or planning pregnancy, and appropriate contraception is required as part of trial participation.

If you are participating in a clinical trial of retatrutide, carry your trial identity card at all times and inform any emergency or out-of-hours clinician that you are enrolled in a trial, so that they can contact the trial team if needed. Report any suspected adverse events to the trial team under the study protocol. If you are not in a trial and encounter a product sold online claiming to be retatrutide, be aware that it is not a licensed product and may be falsified or otherwise harmful.

What is retatrutide's current regulatory status in the UK?

Retatrutide has no MHRA marketing authorisation and can be accessed only within an authorised clinical trial. No timeline for a potential application or authorisation decision can be given.

Retatrutide holds no marketing authorisation in the UK or anywhere else in the world, and it can be accessed only within an authorised clinical trial.^[17] The MHRA authorises medicines for use in the UK, and no such authorisation has been granted for retatrutide. No timeline for a potential application or authorisation decision can be given.

In the UK, the regulatory pathway for a new medicine requires the submission of a comprehensive dossier of safety and efficacy data to the MHRA, which then conducts a scientific assessment before deciding whether to grant a marketing authorisation. Phase 3 trials including TRANSCEND-T2D-1 and the TRIUMPH programme have reported topline results, but the completion of trials, the compilation of a full regulatory dossier and the MHRA's assessment are separate processes, each taking considerable time.

People who are interested in licensed weight-management treatments that are currently available can discuss their options with their GP, who can advise on eligibility and appropriate pathways. Anything sold online or through informal channels as retatrutide is not a licensed product and may pose serious risks to health.

For those with type 2 diabetes or obesity who are seeking information about currently authorised options, tirzepatide (Mounjaro) is MHRA-authorised both for type 2 diabetes and for chronic weight management.^[12][13] Semaglutide is available in two separately licensed presentations: Wegovy is licensed for chronic weight management, while Ozempic is licensed for type 2 diabetes and is not authorised for weight management.^[14][15] NICE makes recommendations on which treatments should be available through the NHS, and local Integrated Care Boards make commissioning decisions based on those recommendations and local priorities.

Frequently Asked Questions